What is HC Wainwright’s Estimate for BOLT FY2024 Earnings?

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) – Analysts at HC Wainwright lowered their FY2024 earnings estimates for Bolt Biotherapeutics in a research report issued to clients and investors on Wednesday, November 13th. HC Wainwright analyst E. White now expects that the company will post earnings per share of ($1.57) for the year, down from their prior forecast of ($1.55). HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Bolt Biotherapeutics’ current full-year earnings is ($1.52) per share. HC Wainwright also issued estimates for Bolt Biotherapeutics’ Q4 2024 earnings at ($0.34) EPS, FY2025 earnings at ($0.94) EPS and FY2026 earnings at ($0.74) EPS.

Bolt Biotherapeutics (NASDAQ:BOLT) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.04). The business had revenue of $1.14 million during the quarter, compared to analyst estimates of $1.02 million. Bolt Biotherapeutics had a negative net margin of 665.56% and a negative return on equity of 64.49%.

Bolt Biotherapeutics Stock Performance

Shares of Bolt Biotherapeutics stock opened at $0.62 on Friday. Bolt Biotherapeutics has a fifty-two week low of $0.55 and a fifty-two week high of $1.56. The firm has a market capitalization of $23.82 million, a P/E ratio of -0.36 and a beta of 0.92. The company has a debt-to-equity ratio of 0.19, a current ratio of 4.28 and a quick ratio of 4.28. The company’s 50 day moving average price is $0.64 and its two-hundred day moving average price is $0.74.

Hedge Funds Weigh In On Bolt Biotherapeutics

Large investors have recently bought and sold shares of the company. Assenagon Asset Management S.A. bought a new stake in Bolt Biotherapeutics during the 2nd quarter worth approximately $26,000. FMR LLC grew its position in shares of Bolt Biotherapeutics by 33.2% in the 3rd quarter. FMR LLC now owns 115,386 shares of the company’s stock valued at $75,000 after buying an additional 28,773 shares during the last quarter. Finally, Acuitas Investments LLC boosted its holdings in Bolt Biotherapeutics by 21.7% in the second quarter. Acuitas Investments LLC now owns 630,507 shares of the company’s stock valued at $473,000 after acquiring an additional 112,555 shares during the last quarter. 86.70% of the stock is currently owned by institutional investors.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.